Science Flare Therapeutics Reveals Promising Data for FX-909 in Cancer Study Flare Therapeutics Inc. has unveiled promising findings from part A of its Phase 1 clinical trial of FX-909, a novel oral small molecule designed... Editorial14 hours ago